Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014
Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014